Rosuvastatin is contraindicated: In patients with hypersensitivity to rosuvastatin or to any of the excipients; in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 times the upper limit of normal (ULN); in patients with severe renal impairment (creatinine clearance <30 mL/min); in patients with myopathy; in patients using a combination of sofosbuvir/velpatasvir/voxilaprevir concomitantly (see Interactions); in patients receiving concomitant ciclosporin; during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.
The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include: Moderate renal impairment (creatinine clearance <60 mL/min); hypothyroidism; personal or family history of hereditary muscular disorders; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate; alcohol abuse; situations where an increase in plasma levels may occur; Asian patients; concomitant use of fibrates (see Precautions, Interactions and Pharmacology: Pharmacokinetics under Actions).
Other Services
Country
Account